KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation

被引：7

作者：

Hua, Qingling ^{[1
]}

Lu, Yuanyuan ^{[2
]}

Wang, Dingxiang ^{[3
]}

Da, Jie ^{[1
]}

Peng, Wanren ^{[1
]}

Sun, Guoping ^{[1
]}

Gu, Kangsheng ^{[1
]}

Wang, Hua ^{[1
]}

Zhu, Yanzhe ^{[1
]}

机构：

[1] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230022, Peoples R China

[2] First Affiliated Hosp, Wannan Med Coll, Dept Radiat Oncol, Wuhu 241004, Peoples R China

[3] fourth peoples Hosp, Dept Psychol, Wuhu 241003, Peoples R China

来源：

TRANSLATIONAL ONCOLOGY | 2023年 / 28卷

关键词：

KIAA1199; O-GlcNAcylation; Endoplasmic reticulum stress; PARP1; SNAI1; EMT; ACTIVATION; PATHWAY; STRESS; GENE;

D O I：

10.1016/j.tranon.2023.101617

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oxaliplatin is a commonly used platinum drug for colorectal cancer (CRC). However, the treatment of CRC by oxaliplatin usually fails because of drug resistance, which results in a huge challenge in the therapy of CRC. Elucidation of molecular mechanisms may help to overcome oxaliplatin resistance of CRC. In our study, we revealed that KIAA1199 can promote oxaliplatin resistance of CRC. Mechanistically, KIAA1199 prevents oxali-platin mediated apoptosis via up-regulated PARP1 derived from reduced endoplasmic reticulum stress induced by protein O-GlcNAcylation. In the meantime, KIAA1199 can also trigger epithelial mesenchymal transition by stabilizing SNAI1 protein via O-GlcNAcylation. Therefore, KIAA1199 has great potential to be a novel biomarker, therapeutic target for oxaliplatin resistance and metastasis of CRC.

引用

页数：13

共 42 条

[1] Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss
Abe, S
Usami, S
Nakamura, Y
[J]. JOURNAL OF HUMAN GENETICS, 2003, 48 (11) : 564 - 570
[2] A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, Sabrina
Corti, Giorgio
Durinikova, Erika
Montone, Monica
Reilly, Nicole M.
Russo, Mariangela
Lorenzato, Annalisa
Arcella, Pamela
Lazzari, Luca
Rospo, Giuseppe
Pagani, Massimiliano
Cancelliere, Carlotta
Negrino, Carola
Isella, Claudio
Bartolini, Alice
Cassingena, Andrea
Amatu, Alessio
Mauri, Gianluca
Sartore-Bianchi, Andrea
Mittica, Gloria
Medico, Enzo
Marsoni, Silvia
Linnebacher, Michael
Abrignani, Sergio
Siena, Salvatore
Di Nicolantonio, Federica
Bardelli, Alberto
[J]. CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1372 - 1384
[3] Arora S., Clinical Cancer Research
[4] Profile of olaparib in the treatment of advanced ovarian cancer
Chase, Dana M.
Patel, Shreya
Shields, Kristin
[J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2016, 8 : 125 - 129
[5] Chen C, 2014, INT J CLIN EXP MED, V7, P4253
[6] Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies
Crea, Francesco
Nobili, Stefania
Paolicchi, Elisa
Perrone, Gabriele
Napoli, Cristina
Landini, Ida
Danesi, Romano
Mini, Enrico
[J]. DRUG RESISTANCE UPDATES, 2011, 14 (06) : 280 - 296
[7] Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer
Cubillos-Ruiz, Juan R.
Bettigole, Sarah E.
Glimcher, Laurie H.
[J]. CELL, 2017, 168 (04) : 692 - 706
[8] Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy
De Mattia, Elena
Cecchin, Erika
Toffoli, Giuseppe
[J]. DRUG RESISTANCE UPDATES, 2015, 20 : 39 - 70
[9] CEMIP (KIAA1199) induces a fibrosis-like process in osteoarthritic chondrocytes
Deroyer, Celine
Charlier, Edith
Neuville, Sophie
Malaise, Olivier
Gillet, Philippe
Kurth, William
Chariot, Alain
Malaise, Michel
de Seny, Dominique
[J]. CELL DEATH & DISEASE, 2019, 10 (2)
[10] New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Dongre, Anushka
Weinberg, Robert A.
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2019, 20 (02) : 69 - 84

← 1 2 3 4 5 →